Apimeds Pharmaceuticals Us earnings were -$40.7M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest APUS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$35.1M, up 2,934.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, APUS reported annual earnings of -$6.0M, with 331.7% growth. The next APUS earnings date is Aug 18, 2026.
Apimeds Pharmaceuticals Us Earnings Reports & History FAQ
What were Apimeds Pharmaceuticals Us's earnings last quarter?
Apimeds Pharmaceuticals Us (NYSEMKT: APUS) reported Q1 2026 earnings per share (EPS) of -$22.60, up 4,420% year over year. Total APUS earnings for the quarter were -$35.06 million. In the same quarter last year, Apimeds Pharmaceuticals Us's earnings per share (EPS) was -$0.50.
When does Apimeds Pharmaceuticals Us report earnings?
The next APUS earnings date is Aug 18, 2026. Add APUS to your watchlist to be reminded of Apimeds Pharmaceuticals Us's next earnings date.
What was APUS's earnings growth in the past year?
As of Apimeds Pharmaceuticals Us's earnings date in Q3 2026, Apimeds Pharmaceuticals Us's earnings has grown year over year. APUS earnings in the past year totalled -$40.66 million.
Is Apimeds Pharmaceuticals Us profitable or losing money?
As of the last Apimeds Pharmaceuticals Us earnings report, Apimeds Pharmaceuticals Us is currently losing money. Apimeds Pharmaceuticals Us's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$40.66 million, a 2,617.98% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.